What makes a PhII drug worth up to $665M? Re­searchers spell it out for No­var­tis

Two weeks ago, No­var­tis stepped in with a deal to buy Se­lexys Phar­ma­ceu­ti­cals and its Phase III-ready sick­le cell dis­ease drug crizan­l­izum­ab, an an­ti-P-se­lectin an­ti­body de­signed to slash the num­ber of va­so-oc­clu­sive pain crises among pa­tients. New Phase II da­ta was promised for ASH this week­end, so we al­ready knew the da­ta were pos­i­tive.

To­day we got some of the de­tails, and they look good for No­var­tis’ new drug (orig­i­nal­ly op­tioned in 2012), at least for the high dose group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER